Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing breast cancer.
Epistemonikos ID: c340ef34e2e45f9e1865fda177deaa1071d60a76
First added on: May 11, 2024